Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.500
+0.200 (4.65%)
At close: Mar 31, 2026, 4:00 PM EDT
4.480
-0.020 (-0.44%)
After-hours: Mar 31, 2026, 7:01 PM EDT
Arbutus Biopharma Employees
Arbutus Biopharma had 19 employees as of December 31, 2025. The number of employees decreased by 25 or -56.82% compared to the previous year.
Employees
19
Change (1Y)
-25
Growth (1Y)
-56.82%
Revenue / Employee
$741,211
Profits / Employee
-$1,763,211
Market Cap
879.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 19 | -25 | -56.82% | 19 | 0 |
| Dec 31, 2024 | 44 | -29 | -39.73% | 44 | 0 |
| Dec 31, 2023 | 73 | -25 | -25.51% | 73 | 0 |
| Dec 31, 2022 | 98 | 11 | 12.64% | 96 | 2 |
| Dec 31, 2021 | 87 | 9 | 11.54% | 85 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Phathom Pharmaceuticals | 371 |
| UroGen Pharma | 291 |
| Xencor | 260 |
| MapLight Therapeutics | 133 |
| Inhibrx Biosciences | 110 |
| Cullinan Therapeutics | 109 |
| Janux Therapeutics | 109 |
ABUS News
- 8 days ago - Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant - WSJ
- 4 weeks ago - Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute - Reuters
- 4 weeks ago - Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 4 weeks ago - Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 4 weeks ago - Moderna Resolves Global Patent Litigation with Arbutus/Genevant - Accesswire
- 2 months ago - Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts - Seeking Alpha
- 4 months ago - Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire